Impact of postnatal blockade of N-methyl-d-aspartate receptors on rat behavior: A search for a new developmental model of schizophrenia

Neuroscience

Volumn 153, Issue 4, 2008, Pages 1370-1379

  Wedzony, K ^a   Fijal, K ^a   Mackowiak, M ^a   Chocyk, A ^a   Zajaczkowski, W ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

developmental model of schizophrenia; NMDA receptors; psychomotor agitation; sensorimotor gating; social interaction; working memory

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; COGNITIVE DEFECT; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RESTLESSNESS; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; WORKING MEMORY;

2-AMINO-5-PHOSPHONOVALERATE; AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEMALE; MALE; MAZE LEARNING; PHENCYCLIDINE; PREGNANCY; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 43949126163     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.03.016     Document Type: Article

References (77)

1. Akil M., Edgar C.L., Pierri J.N., Casali S., and Lewis D.A. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47 (2000) 361-370
2. Akil M., Pierri J.N., Whitehead R.E., Edgar C.L., Mohila C., Sampson A.R., and Lewis D.A. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156 (1999) 1580-1589
3. Becker A., Peters B., Schroeder H., Mann T., Huether G., and Grecksch G. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 687-700
4. Black M.D., Selk D.E., Hitchcock J.M., Wettstein J.G., and Sorensen S.M. On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology 38 (1999) 1299-1306
5. Black M.D., Simmonds J., Senyah Y., and Wettstein J.G. Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology 42 (2002) 414-420
6. Boog G. Obstetrical complications and subsequent schizophrenia in adolescent and young adult offspring: is there a relationship?. Eur J Obstet Gynecol Reprod Biol 114 (2004) 130-136
7. Borrell J., Vela J.M., Arevalo-Martin A., Molina-Holgado E., and Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26 (2002) 204-215
8. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
9. Braff D.L., and Swerdlow N.R. Neuroanatomy of schizophrenia. Schizophr Bull 23 (1997) 509-512
10. Broadbelt K., Byne W., and Jones L.B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res 58 (2002) 75-81
11. Cardno A.G., and Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 97 (2000) 12-17
12. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 32 (2000) 476-509
13. Dall'Olio R., Facchinetti F., Contestabile A., and Gandolfi O. Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience 63 (1994) 451-455
14. Diergaarde L., Gerrits M.A., Stuy A., Spruijt B.M., and van Ree J.M. Neonatal amygdala lesions and juvenile isolation in the rat: differential effects on locomotor and social behavior later in life. Behav Neurosci 118 (2004) 298-305
15. Diergaarde L., Spruijt B.M., Wolterink-Donselaar I.G., Gerrits M.A., and van Ree J.M. Neonatal amygdala lesions affect appetitive motivational and consummatory aspects of social behavior in the rat. Behav Neurosci 119 (2005) 814-820
16. Elmer G.I., Sydnor J., Guard H., Hercher E., and Vogel M.W. Altered prepulse inhibition in rats treated prenatally with the antimitotic Ara-C: an animal model for sensorimotor gating deficits in schizophrenia. Psychopharmacology (Berl) 174 (2004) 177-189
17. Featherstone R.E., Rizos Z., Nobrega J.N., Kapur S., and Fletcher P.J. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32 (2007) 483-492
18. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J Psychiatr Res 17 (1982) 319-334
19. Fiske B.K., and Brunjes P.C. NMDA receptor regulation of cell death in the rat olfactory bulb. J Neurobiol 47 (2001) 223-232
20. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
21. Gould E., Cameron H.A., and McEwen B.S. Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J Comp Neurol 340 (1994) 551-565
22. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
23. Hoptman M.J., Volavka J., Czobor P., Gerig G., Chakos M., Blocher J., Citrome L.L., et al. Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. J Neuropsychiatry Clin Neurosci 18 (2006) 509-515
24. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
25. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
26. Kalus P., Muller T.J., Zuschratter W., and Senitz D. The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. Neuroreport 11 (2000) 3621-3625
27. Kasai K., Iwanami A., Yamasue H., Kuroki N., Nakagome K., and Fukuda M. Neuroanatomy and neurophysiology in schizophrenia. Neurosci Res 43 (2002) 93-110
28. Katz I., Kim J., Gale K., and Kondratyev A. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther 322 (2007) 494-500
29. Krase W., Koch M., and Schnitzler H.U. Glutamate antagonists in the reticular formation reduce the acoustic startle response. Neuroreport 4 (1993) 13-16
30. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
31. Lecrubier Y., Perry R., Milligan G., Leeuwenkamp O., and Morlock R. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey. Eur Psychiatry 22 (2007) 371-379
32. Lehmann J., Stohr T., and Feldon J. Long-term effects of prenatal stress experiences and postnatal maternal separation on emotionality and attentional processes. Behav Brain Res 107 (2000) 133-144
33. Lema Tome C.M., Nottingham C.U., Smith C.M., Beauchamp A.S., Leung P.W., and Turner C.P. Neonatal exposure to MK801 induces structural reorganization of the central nervous system. Neuroreport 17 (2006) 779-783
34. Li H.P., Honma S., Miki T., Takeuchi Y., Takeuchi K., and Kawano H. Multiple defects in the formation of rat cortical axonal pathways following prenatal X-ray irradiation. Eur J Neurosci 21 (2005) 1847-1858
35. Lipska B.K., Al Amin H.A., and Weinberger D.R. Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage. Neuropsychopharmacology 19 (1998) 451-464
36. Lipska B.K., Aultman J.M., Verma A., Weinberger D.R., and Moghaddam B. Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27 (2002) 47-54
37. Lipska B.K., Chrapusta S.J., Egan M.F., and Weinberger D.R. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse 20 (1995) 125-130
38. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., and Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 122 (1995) 35-43
39. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
40. Lysaker P.H., and Salyers M.P. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 116 (2007) 290-298
41. Martinez Z.A., Ellison G.D., Geyer M.A., and Swerdlow N.R. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21 (1999) 28-39
42. McDonald J.W., and Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Brain Res Rev 15 (1990) 41-70
43. Mickley G.A., Kenmuir C.L., McMullen C.A., Snyder A., Yocom A.M., Likins-Fowler D., Valentine E.L., et al. Long-term age-dependent behavioral changes following a single episode of fetal N-methyl-D-aspartate (NMDA) receptor blockade. BMC Pharmacol 4 (2004) 28
44. Mitchell P.J., and Redfern P.H. Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635. Behav Pharmacol 8 (1997) 585-606
45. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
46. Monti B., and Contestabile A. Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum. Eur J Neurosci 12 (2000) 3117-3123
47. Nolan K.A., Volavka J., Mohr P., and Czobor P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr Serv 50 (1999) 787-792
48. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., and Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59 (2006) 546-554
49. Palmer A.A., Printz D.J., Butler P.D., Dulawa S.C., and Printz M.P. Prenatal protein deprivation in rats induces changes in prepulse inhibition and NMDA receptor binding. Brain Res 996 (2004) 193-201
50. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
51. Powell C.M., and Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol Psychiatry 59 (2006) 1198-1207
52. Powell S.B., Geyer M.A., Gallagher D., and Paulus M.P. The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behav Brain Res 152 (2004) 341-349
53. Rapoport J.L., Addington A.M., Frangou S., and Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10 (2005) 434-449
54. Rioux L., Nissanov J., Lauber K., Bilker W.B., and Arnold S.E. Distribution of microtubule-associated protein MAP2-immunoreactive interstitial neurons in the parahippocampal white matter in subjects with schizophrenia. Am J Psychiatry 160 (2003) 149-155
55. Sachs G.S. A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry 67 Suppl 10 (2006) 5-12
56. Scallet A.C., Schmued L.C., Slikker Jr. W., Grunberg N., Faustino P.J., Davis H., Lester D., et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci 81 (2004) 364-370
57. Schiffelholz T., Hinze-Selch D., and Aldenhoff J.B. Perinatal MK-801 treatment affects age-related changes in locomotor activity from childhood to later adulthood in rats. Neurosci Lett 360 (2004) 157-160
58. Selemon L.D., and Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45 (1999) 17-25
59. Silva-Gomez A.B., Bermudez M., Quirion R., Srivastava L.K., Picazo O., and Flores G. Comparative behavioral changes between male and female postpubertal rats following neonatal excitotoxic lesions of the ventral hippocampus. Brain Res 973 (2003) 285-292
60. Spiera R.F., and Davis M. Excitatory amino acid antagonists depress acoustic startle after infusion into the ventral nucleus of the lateral lemniscus or paralemniscal zone. Brain Res 445 (1988) 130-136
61. Stefani M.R., and Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57 (2005) 433-436
62. Swanson J.W., Swartz M.S., Van Dorn R.A., Elbogen E.B., Wagner H.R., Rosenheck R.A., Stroup T.S., et al. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 63 (2006) 490-499
63. Talamini L.M., Koch T., Luiten P.G., Koolhaas J.M., and Korf J. Interruptions of early cortical development affect limbic association areas and social behaviour in rats: possible relevance for neurodevelopmental disorders. Brain Res 847 (1999) 105-120
64. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 47 (2000) 210-220
65. Vaillancourt C., and Boksa P. Birth insult alters dopamine-mediated behavior in a precocial species, the guinea pig. Implications for schizophrenia. Neuropsychopharmacology 23 (2000) 654-666
66. Van den Berg C.L., van Ree J.M., and Spruijt B.M. Sequential analysis of juvenile isolation-induced decreased social behavior in the adult rat. Physiol Behav 67 (1999) 483-488
67. Van den Buuse M., Garner B., and Koch M. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. Curr Mol Med 3 (2003) 459-471
68. Volk D.W., and Lewis D.A. Effects of a mediodorsal thalamus lesion on prefrontal inhibitory circuitry: implications for schizophrenia. Biol Psychiatry 53 (2003) 385-389
69. Wang C., Anastasio N., Popov V., Leday A., and Johnson K.M. Blockade of N-methyl-D-aspartate receptors by phencyclidine causes the loss of corticostriatal neurons. Neuroscience 125 (2004) 473-483
70. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
71. Wang C.Z., and Johnson K.M. The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32 (2007) 1178-1194
72. Wedzony K., Fijal K., and Chocyk A. Blockade of NMDA receptors in postnatal period decreased density of tyrosine hydroxylase immunoreactive axonal arbors in the medial prefrontal cortex of adult rats. J Physiol Pharmacol 56 (2005) 205-221
73. Wedzony K., Fijal K., and Mackowiak M. Alterations in the dendritic morphology of prefrontal pyramidal neurons in adult rats after blockade of NMDA receptors in the postnatal period. Brain Res 1062 (2005) 166-170
74. Wedzony K., Golembiowska K., and Zazula M. Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol 350 (1994) 555-562
75. Wedzony K., Mackowiak M., Zajaczkowski W., Fijal K., Chocyk A., and Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23 (2000) 547-559
76. 2+ deficiency. J Neurochem 85 (2003) 525-533
77. Zajaczkowski W., Czyrak A., and Wedzony K. A competitive antagonist of NMDA receptors CGP 40116 attenuates experimental symptoms of schizophrenia evoked by MK-801. Pol J Pharmacol 55 (2003) 703-711